ESR1 and breast cancer: Although in the TMA there were no differences between the CrkL staining and the PR(−) versus PR(+) and ER(−) versus ER(+) status (p = 0.27 and 0.11, respectively), following studies will have to examine the relationship between the breast cancer subtype and the levels of the soluble CrkL in the patients’ sera.